Autologous Cell Therapy Market - Databook 2025 to 2034

The global autologous cell therapy market size was evaluated at USD 5,430 million in 2024 and is expected to grow around USD 40,020 million by 2034, registering a CAGR of 22.11% from 2025 to 2034.

Highlights of the Autologous Cell Therapy Market 

• North America dominated the global autologous cell therapy market in 2024. 
• Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period. 
• By therapy type, the non-stem cell therapies segment held a dominant presence in the market in 2024. 
• By therapy type, the stem cell therapies segment is expected to grow at the fastest rate in the market during the forecast period. 
• By therapeutic area, the oncology segment dominated the autologous cell therapy market in 2024. 
• By therapeutic area, the dermatology segment is projected to experience the highest growth rate in the market. 

Industry Valuation and Growth Rate Projection

Autologous cell therapies are at the cutting edge of cell and gene therapy transformation. This cell therapy signifies that the cells are gathered from the patient's own body. The cells are generally removed and changed outside the body, and later, the processed cells are put back into the body. In such therapies, cells from a definite patient are basically collected, function ex vivo, and then restored to the same individual.

Autologous Cell Therapy Market: Stats and Figures 

• In November 2023, Selecta Biosciences, Inc. (SELB) declared that it has incorporated biotechnology firms Cartesian Therapeutics, Inc. In association with the merger, Selecta declared a $60.25 million private support guided by Timothy Springer, an associate of the Selecta Board of Directors.
• The 2024 yearly analysis of the Cell and Gene Therapy Catapult emphasized that the UK remains a significant market for thriving and marketing the recently developed CGT. Presently, several latest CGTs have been accepted, including the analysis of hemophilia A and hematological malignancies. 

How AI Has Benefitted the Autologous Cell Therapy Market 

AI has the potency to transform cell therapy by permitting researchers to understand huge amounts of information and generate new insights into how cells function. One of the key advantages of utilizing AI in cell therapy is its capability to assist in identifying the best cells for a specific patient.

• By determining a patient’s genetic data and medical history, AI algorithms can forecast which cells will most probably effectively treat their condition.
• AI can also assist researchers in detecting the optimal conditions for growing cells. In cell therapy, the delivery of cells to the aim site is a vital step that can remarkably impact the success of the treatment.
• AI can assist in enhancing the delivery of cells by understanding the route of administration and permitting the cells to reach the aim site effectively.
• AI can also help analyze the timing of cell delivery and optimal dose to maximize therapeutic advantages. 
• In addition, it can help in tracking the cells after delivery, tailoring their migration and survival, and analyzing any adverse effects.

Industry Leader Announcements

• Vipul, the Founder of Advancells

He believes stem cells are the prospective of healthcare, is targeted on creating Advancells a therapy provider even as the most Indian firms concentrate on research and banking.

"I got into it because it can save lives; research is only reducing costs,” says Vipul, the Founder of Advancells.

• Siddhartha Mukherjee, Cancer Physician, Author, and Co-Founder of Immuneel Therapeutics 

"What started as a dinner-table conversation has come to fruition with the approval of a lifesaving CAR-T therapy."

Geographical Insights

The global market is experiencing significant growth, with North America maintaining its position as the dominant region while Europe emerges as the fastest-growing market. In the APAC region, China stands out as a driver of growth in the space.

North America

North America dominated the global market in 2024. This dominance is attributed to several key factors, such as the area has become greatly competitive since many years because of major players such as BrainStorm Cell Therapeutics functioning there, also growing population, burdens, numerous immunological advantages, and lowered rejection risk have developed new expansion opportunities for the market.

Europe 

Europe is projected to be the fastest-growing region in the market. This area has a strong existence in the sector of cell therapy research and regenerative medicine. The region's advantages come from supportive government initiatives, a solid healthcare system, and combining working between research organizations, academic institutions, and major industry players. The European Medicines Agency (EMA) plays a crucial role in regulating and accepting cell therapies, offering a clear pathway for market entry.

China and APAC

The Asia Pacific (APAC) region is experiencing rapid growth in the oncology market. China stands out as the fastest-growing within APAC. They are funded heavily in regenerative medicine R&D. The region drives a large pool of population, a growing incidence of chronic disorders, and an increasing need for advanced healthcare solutions. Furthermore, favorable government policies, raised funding, and the existence of market players are boosting the expansion of the autologous cell therapy market.

Recent Developments

• In April 2025, UC Davis Health started a new cell therapy trial for different chronic kidney disease patients. 
• In January 2022, Chamath Palihapitiya’s unique purpose acquisition firm is throwing its weight behind ProKidney. The merger will provide ProKidney $825 million to support phase 3 development of a cell therapy intended to slow, reverse, and stabilize the decline in kidney function.

Competitive Landscape

The competitive landscape of the autologous cell therapy market is differentiated by its variety of players competing to capture market share via product innovation, aggressive marketing efforts, and strategic partnerships. Major players in the market, such as established autologous cellular immunotherapies producers, customized autologous cell therapy firms, and developing startups to disturb the market with innovative ideas.

• Company Name: Bayer AG
• Year of Incorporation: 1863
• Headquarters: Leverkusen, Germany

Bayer AG functions its business via segments like Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. The firm provides induced pluripotent stem cells. They are created by reprogramming mature body cells to function as embryonic stem cells, which are injected to repair diseased tissue in patients.

• Company Name: Holostem Terapie Avanzate Srl
• Year of Incorporation: 2008
• Headquarters: Modena, Emilia-Romagna, Italy

Holostem Terapie Avanzate Srl functions its business via a unified business form. Holoclar is the main product of the firm. It is an evolved therapy medicinal product consisting of stem cells designated to fix the cornea after injury.